The groups spend big on Terns and Arcellx.
ApexOnco Front Page
Recent articles
J&J’s Tecvayli/Darzalex nod was the second under a new priority voucher scheme.
The Stellar-303 trial of zanzalintinib hits, but the discussant asks for more data and flags toxicity.
Harmoni-6 succeeds in first-line lung cancer, but the focus is on changes to Harmoni-3.
The first TUB-040 data come just after Tubulis raised €308m.
After promising early data in head and neck, J&J plans a new phase 3, Origami-5.
Full data from Edge-Gastric are presented at ESMO.
The battle intensifies as LY4170156 matches torvuta-S with activity in FRα <25% expresers.
